Literature DB >> 19995405

Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy.

P C J Armstrong, A-R A Dhanji, A T Tucker, J A Mitchell, T D Warner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19995405     DOI： 10.1111/j.1538-7836.2009.03714.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  19 in total

Review 1.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.

Authors:  Joo-Yong Hahn; Young Bin Song; Ju-Hyeon Oh; Woo Jung Chun; Yong Hawn Park; Woo Jin Jang; Eul-Soon Im; Jin-Ok Jeong; Byung Ryul Cho; Seok Kyu Oh; Kyeong Ho Yun; Deok-Kyu Cho; Jong-Young Lee; Young-Youp Koh; Jang-Whan Bae; Jae Woong Choi; Wang Soo Lee; Hyuck Jun Yoon; Seung Uk Lee; Jang Hyun Cho; Woong Gil Choi; Seung-Woon Rha; Joo Myung Lee; Taek Kyu Park; Jeong Hoon Yang; Jin-Ho Choi; Seung-Hyuck Choi; Sang Hoon Lee; Hyeon-Cheol Gwon
Journal:  JAMA       Date:  2019-06-25       Impact factor: 56.272

3.  Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation.

Authors:  Joanna Lecka; Manjit Singh Rana; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin?

Authors:  Wen-Han Feng; I-Chang Hsieh; Yi-Heng Li
Journal:  Acta Cardiol Sin       Date:  2021-01       Impact factor: 2.672

Review 5.  The role of oral anticoagulant therapy in patients with acute coronary syndrome.

Authors:  Jae Youn Moon; Deepa Nagaraju; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Ther Adv Hematol       Date:  2017-10-13

Review 6.  Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.

Authors:  Nalyaka Sambu; Nick Curzen
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 7.  Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.

Authors:  Timothy D Warner; Sven Nylander; Carl Whatling
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

8.  Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD.

Authors:  Saskia H Meves; Thomas Hummel; Heinz G Endres; Nora Mayböck; Andreas F C Kaiser; Kay D Schröder; Katja Rüdiger; Ursula Overbeck; Achim Mumme; Andreas Mügge; Horst Neubauer
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

9.  Clopidogrel preserves whole kidney autoregulatory behavior in ANG II-induced hypertension.

Authors:  David A Osmond; Shali Zhang; Jennifer S Pollock; Tatsuo Yamamoto; Carmen De Miguel; Edward W Inscho
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-29

Review 10.  Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After PCI.

Authors:  Ali Ayoub; Karnika Ayinapudi; Ahmed Al-Ogaili; Muhammad Siyab Panhwar; Wael Dakkak; Thierry LeJemtel
Journal:  Am J Cardiovasc Drugs       Date:  2021-03       Impact factor: 3.571
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.